eligibility_summary
Eligible: patients with recurrent low-grade (Ta) NMIBC with visible tumor (cystoscopy within 12 weeks), intermediate risk (multiple tumors, >1 occurrence within 1 year, early recurrence, solitary >3 cm, prior intravesical failure), ECOG 0-2. Exclude: newly diagnosed, any high-grade/T1/CIS/MIBC/metastatic UC, voiding issues, severe ocular disease, IBD needing immunosuppression, uncontrolled CV/cerebrovascular disease, other active cancers within 3 years, pneumonitis/ILD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06637423 tests intravesical sacituzumab tirumotecan (SKB264/MK-2870), an antibody–drug conjugate (ADC). Mechanism: a humanized anti-TROP2 monoclonal antibody binds TROP2 on urothelial tumor cells, is internalized, and releases a topoisomerase I inhibitor payload (camptothecin-class), causing DNA single-strand breaks, replication stress, S‑phase arrest, and apoptotic cell death, a bystander effect may occur. Target cells/pathways: TROP2-overexpressing urothelial carcinoma cells in the bladder, receptor-mediated endocytosis of TROP2, DNA replication/Topoisomerase I and downstream DNA-damage response pathways. Rescue/supportive meds are symptomatic and not tumor-targeted.